Deborah Sampson, left, a nurse at a University of Washington Medical Center clinic in Seattle, gives a Pfizer COVID-19 vaccine shot to a 20-month-old child, June 21, 2022, in Seattle. The U.S. on Thursday, Dec. 8, 2022 open doses of the updated COVID-19 vaccines for most children younger than age 5. The Food and Drug Administration's decision aims to better protect the littlest kids from severe COVID-19 at a time when children’s hospitals already are packed with tots suffering a variety of other respiratory illnesses, too. (AP Photo/Ted S. Warren, file)
Confidence in the scientific community declined among U.S. adults in 2022, a major survey shows, driven by a partisan divide in views of both science and medicine that emerged during the COVID-19 pandemic.
Overall, 39% of U.S. adults said they had “a great deal of confidence” in the scientific community, down from 48% in 2018 and 2021. That's according to the General Social Survey, a long-running poll conducted by NORC at the University of Chicago that has monitored Americans’ opinions on key topics since 1972.
An additional 48% of adults in the latest survey reported “only some” confidence, while 13% reported “hardly any,” according to an analysis of the survey by The Associated Press-NORC Center for Public Affairs Research.
“It doesn’t look all that dramatic when you just look at the trends for the overall public,” Benz said. “But when you dig into that by people’s political affiliations, there’s a really stark downturn and polarization.”
Between surveys in 2018 and 2021, as the pandemic took hold, the major parties’ trust levels headed in opposite directions. Democrats reported a growing level of confidence in science in 2021 — perhaps as a “rallying effect” around things like COVID-19 vaccines and prevention measures, Benz said. At the same time, Republicans saw their confidence start to plummet.
In the 2022 survey, Democrats’ confidence fell back to around pre-pandemic levels, with 53% reporting a great deal of confidence compared with 55% in 2018. But Republicans’ confidence continued its downward trend, dropping to 22% from 45% in 2018. Confidence in medicine has also grown more polarized since 2018. That year, Democrats and Republicans were about equally likely to say they had high confidence. By 2022, though, Republicans’ confidence had fallen to 26%, while Democrats’ has remained about the same as it was before the pandemic, at 42%.
Overall, 34% of Americans reported a great deal of confidence in medicine in 2022, compared with 39% before the pandemic.
Generally, scientists have had a high level of trust compared to other groups in the U.S., said John Besley, who studies public opinion about science at Michigan State University. And even with the latest declines, confidence in science is still higher than many other institutions, he pointed out.
But the split between political parties is a cause for concern, experts said.
“You can definitely see the impact here of people taking cues from their political leaders,” Benz said.
For Sudip Parikh, CEO of the American Association for the Advancement of Science, the drops were “disappointing but not surprising.” He sees them as part of an “overall pulling apart of our communities” and a loss of trust in many institutions.
The latest survey found that distrust has grown for some other groups, too. According to the 2022 survey, confidence in the Supreme Court has plunged to its lowest level in at least 50 years. Americans also reported lower levels of trust in education, the press, major companies and organized religion.
Besley said that scientists should communicate about their motives to help show that they are trustworthy: “Not only do we have some expertise, but that also we’re using that expertise to try to make the world better,” he said.
Parikh thought the stakes are high for rebuilding trust in science — and doing so across political lines.
“Science must be bipartisan,” he said. “The causes of Alzheimer’s are the same whether you’re a Republican or a Democrat. The fusion that goes on in the sun is the same whether you live in Topeka or you live in San Francisco.”
The General Social Survey has been conducted since 1972 by NORC at the University of Chicago. Sample sizes for each year’s survey vary from about 1,500 to about 4,000 adults, with margins of error falling between plus or minus 2 percentage points and plus or minus 3.1 percentage points. The most recent survey was conducted May 5, 2022, through Dec. 20, 2022, and includes interviews with 3,544 American adults. Results for the full sample have a margin of error of plus or minus 3 percentage points.
The FDA has granted emergency use authorization to Pfizer's pill to treat covid-19. The treatment, called Paxlovid, is the first antiviral covid-19 pill that people can take at home.
Pfizer says the pill can reduce the risk of severe illness by 90 percent and is intended for people at high risk for severe disease, including those over 65, people with obesity, diabetes, or a weakened immune system. Professor Peter Pitts, Founder, Center for Medicine in the Public Interest & Former FDA Associate joined Wake Up with Cheddar to discuss.
Ahead of a four day week for the markets due to the upcoming Christmas holiday, investors hoping for a quiet end to the year, or even a Santa Claus rally, may not be in luck. Investors are still digesting the latest from the Fed regarding a quicker than expected taper, as well as ever increasing blow back as the Omicron variant spreads. Octavio Marenzi, CEO of Opimas LLC, explains why the markets have been so volatile ever since the emergence of the latest variant and what to expect going forward into 2022.
Carlo and Baker cover the heartening news on the Covid front ahead of the holiday, plus President Biden punting student loan repayments again, a new space telescope and Love, Hate, Ate: Christmas Eve Eve Edition!
Pfizer, one of the makers of a currently available COVID-19 vaccine, has taken another critical step forward in combatting the pandemic by getting regulatory approval for Paxlovid, a pill treatment rather than IV or injection as others have been. Dr. Purvi Parikh, an immunologist with the Allergy and Asthma Network, spoke to Cheddar about the ramifications of the authorization. "This is huge, especially because we know early treatment does keep people out of the hospital, especially with this antiviral," Parikh said. "The fact that people can start a regimen at home so they don't have to leave and further expose others is a big breakthrough." She also explained how the drug is a combination of two antiviral medications that are not without its risks but should be safe over the short term.
This year's worldwide semiconductor shortage limited the supply of everything from new cars to smartphones; and now, many in the chip industry expect the shortage to continue deep into 2022, and maybe even 2023. Semiconductor senior research analyst for Robert W. Baird & Co., Tristan Gerra, joins Cheddar News' Closing Bell to discuss.
Direct health care company Nomi Health recently raised $110 million in a Series A round. Nomi Health lets public and private organizations directly purchase healthcare at reduced costs, and pay providers in real-time. It also delivers healthcare directly to under-served communities via its fleet of mobile care units, which the company says is the largest in the country. Nomi Health says its mission is to improve the health care experience for all Americans. Nomi Health CEO Mark Newman joined Cheddar News' Closing Bell to discuss.
The airline industry says it is contending with staff shortages that threaten to hamper operations amid the COVID resurgence, andDelta Airlines CEO Ed Bastian called on the CDC to revise its guidance for vaccinated workers who test positive from a 10-day quarantine to just five. Chuck Liberman, chief investment officer and managing partner at Advisors Capital Management LLC, joined Cheddar to talk about the current guidance on isolation and why he believes the omicron variant calls for more relaxed guidance given its reportedly mild symptoms.
The boys discuss President Biden's plans to send out free rapid tests as the testing supply chain starts to buckle ahead of the holidays. Also, why aren't Americans having more babies, and The Matrix returns.
NASA is launching its new generation of space telescopes just before Christmas. The James Webb Space Telescope, set to launch on December 24th, will succeed the Hubble space telescope as the world's most powerful complex space observatory. The project has been 30 years in the making and is one of the most highly anticipated space science missions of the 21st century. Klaus Pontoppidan, astronomer and JWST Project Scientist at the Space Telescope Science Institute joined Cheddar's Opening Bell to discuss.
With Omicron becoming the dominant COVID-19 variant in the U.S., President Joe Biden announced that he will make 500 million rapid tests available to Americans in January 2022. Cheddar News speaks with Dr. Shereef Elnahal, President and CEO of University Hospital why testing is key to combatting the spread of the virus.
